The CDC’s decision could potentially increase the value of the company acquired by Bill Gates and George Soros.
On Saturday the CDC announced that PCR tests will soon no longer be available for emergency use to determine whether individuals have contracted COVID-19, and seemed to tacitly admit that the tests are unable to differentiate between COVID-19 and influenza viruses. Many of National File’s readers noted that this development came less than one week after Bill Gates and George Soros announced their intention to buy a COVID-19 test manufacturer based in the United Kingdom.
As National File reported, the CDC declared that it will withdraw its emergency use application for the controversial PCR tests on December 31, 2021, and is urging clinics and hospitals around the country to immediately begin the process of using new tools better able to “facilitate detection and differentiation of SARS-CoV-2 and influenza viruses” because “Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season.”
It appears clinics will have a new choice for COVID-19 tests by time the PCR tests are phased out: Mologic, a company in the United Kingdom that manufactures COVID-19 tests and is expected to be purchased by a new initiative run by George Soros and Bill Gates, Global Access Health.
